CVS Caremark®

|  |
| --- |
| Reference number(s) |
| 6237-A |

# Specialty Guideline Management Loqtorzi

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
| --- | --- |
| Loqtorzi | toripalimab-tpzi |

## Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### FDA-Approved Indications1

* Loqtorzi is indicated, in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC).
* Loqtorzi is indicated, as a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.

### Compendial Uses2,3

Nasopharyngeal Carcinoma (NPC)

Anal Carcinoma

Small Bowel Adenocarcinoma

Colorectal Cancer

Non-small Cell Lung Cancer (NSCLC)

All other indications are considered experimental/investigational and not medically necessary.

## Documentation

Submission of the following information is necessary to initiate the prior authorization review:

* Documentation of laboratory report confirming microsatellite instability-high (MSI-H), mismatch repair deficient (dMMR) or polymerase epsilon/delta (POLE/POLD1) tumor status, where applicable.
* Documentation of the absence of epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations, where applicable.

## Exclusions

Coverage will not be provided for members who have experienced disease progression while on PD-1 or PD-L1 inhibitor therapy.

## Coverage Criteria

### Nasopharyngeal Carcinoma (NPC)1,2

Authorization of 6 months may be granted when either of the following criteria are met:

* The requested medication will be used in combination with cisplatin and gemcitabine for the treatment of unresectable, metastatic or recurrent locally advanced NPC.
* The requested medication will be used as a single agent for treatment of recurrent, unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.

### Anal Carcinoma2

Authorization of 6 months may be granted as a single agent for subsequent treatment of metastatic anal carcinoma if the member has not received prior immunotherapy.

### Small Bowel Adenocarcinoma2

Authorization of 6 months may be granted as a single agent for treatment of locally unresectable, medically inoperable, advanced or metastatic small bowel adenocarcinoma for microsatellite instability-high (MSI-H), or deficient mismatch repair (dMMR), or polymerase epsilon/delta (POLE/POLD1) mutation with ultra-hypermutated phenotype tumors.

### Colorectal Cancer2

Authorization of 6 months may be granted as a single agent for the treatment of unresectable, medically inoperable, advanced, or metastatic colorectal cancer, including appendiceal adenocarcinoma, for microsatellite instability-high (MSI-H), or deficient mismatch repair (dMMR), or polymerase epsilon/delta (POLE/POLD1) mutation with ultra-hypermutated phenotype tumors.

### Non-small Cell Lung Cancer (NSCLC)3

Authorization of 6 months may be granted:

* For treatment of advanced NSCLC when there are no EGFR or ALK mutations (unless testing is not feasible due to insufficient tissue) and the requested medication will be used as a first-line treatment in combination with platinum-doublet chemotherapy and then continued as single agent maintenance therapy.
* As neoadjuvant treatment if there are no EGFR or ALK mutations (unless testing is not feasible due to insufficient tissue) when used in combination with platinum-doublet chemotherapy and then continued as single agent adjuvant therapy after surgery.

## Continuation of Therapy

Nasopharyngeal Carcinoma

Authorization of 6 months (for up to 24 months total when being used as first line therapy) may be granted for continued treatment in members requesting reauthorization for nasopharyngeal carcinoma when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

### Neoadjuvant NSCLC

Authorization of 6 months may be granted (up to 13 cycles total) for continued treatment in members requesting reauthorization for neoadjuvant treatment of NSCLC who have not experienced disease progression or an unacceptable toxicity.

NSCLC

Authorization of 6 months (for up to 24 months total) may be granted for continued treatment in members requesting reauthorization for NSCLC when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

All Other Indications

Authorization of 6 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria section when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

## References

1. Loqtorzi [package insert]. Redwood City, CA: Coherus BioSciences, Inc; October 2024.
2. The NCCN Drugs & Biologics Compendium 2025 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed March 4, 2025.
3. IBM Micromedex® DRUGDEX® (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at https://www.micromedexsolutions.com Accessed March 6, 2025.